What Is It about? {#sec1_1}
=================

This case report is about a patient diagnosed with a pulmonary MALT lymphoma, a rare lung tumor with an unspecific clinical and imaging presentation, needing biopsy for diagnosis. Surgery was needed both for diagnostics and therapy, and after tumor excision the patient had no relapse with no need for additional treatment. Due to the few cases reported, there are no international recommendations guiding the therapeutic approach. This case reinforces expert opinion that surgery should be the proposed approach for localized disease.

Established Facts {#sec1_2}
=================

-   Primary pulmonary MALT lymphoma is a rare entity.

-   Radiologic presentation is highly heterogeneous.

-   There are no current guidelines for treatment standardization.

Novel Insights {#sec1_3}
==============

-   Surgical excision may be the ideal approach for localized disease.

-   Surgery can be curative with no need for additional therapy.

Introduction {#sec1_4}
============

Primary pulmonary lymphoma (PPL) is a clonal lymphoid proliferation affecting one or both lungs (parenchyma and/or bronchi) in a patient with no detectable extra-pulmonary involvement at diagnosis or during the subsequent 3 months \[[@B1], [@B2]\]. MALT (mucosa-associated lymphoid tissue)-derived lymphoma, also known as bronchial-associated lymphoid tissue lymphoma, is rare, representing 0.5% of all primary lung cancers \[[@B3], [@B4]\]. However, it comprises 80--90% of all reported PPL \[[@B5]\]. It develops more often in the sixth and seventh decades of life with no gender predominance \[[@B6]\], frequently in patients with a chronic inflammatory or infectious background \[[@B7], [@B8]\].

Case Report {#sec1_5}
===========

We describe the case of a 74-year-old female non-smoker, with previous relevant history of a healed pulmonary tuberculosis, arterial hypertension, and fibromyalgia. She had had an uneventful follow-up and had remained asymptomatic ever since. In a routine visit, her rheumatologist required an abdominal CT to investigate an apparent abdominal mass noted at the physical examination. It ruled out an abdominal pathology but identified a right inferior lobe (RIL) rounded opacity, for which she was referred for investigation in the pulmonology clinic.

She underwent a thoracic CT, which identified a grossly rounded RIL opacity (4 × 3.4 cm), suspicious of an atypical lesion, mild scarring RIL abnormalities, small calcified mediastinal and hepatic (hilar and portal vein) adenopathies, and multiple calcified millimetric hepatosplenic foci, interpreted in the setting of a probable granulomatous disease (Fig. [1](#F1){ref-type="fig"}).

An 18-fluoro-2-deoxy-D-glucose positron emission tomography (^18^F-FDG-PET) was performed, which showed an abnormal ^18^F-FDG uptake (SUV 4.7) suggestive of cancer, matching the location of the RIL mass previously identified on the thoracic CT. The scan also showed a diffuse splenic (SUV 3.9) and hepatic (SUV 4.0) marker uptake, supporting a diffuse inflammatory behavior.

The patient was then submitted to a flexible bronchoscopy for etiological investigation. It revealed a diffuse hyperemia at the tracheal and bronchial mucosa with no other relevant endoscopic abnormalities. The CT-guided trans-bronchial needle biopsies, bronchial brushing, and respiratory secretions analysis were inconclusive for diagnostic purposes.

To clarify the nature of the lesion she was then referred for surgical biopsy with extemporaneous examination. An apical RIL segmentectomy was performed and the pathological examination identified a 3.5-cm mass, in major axis with clear margins. The direct microscopic and immunohistochemical exams revealed a small lymphocytic proliferation with several lymphoepithelial lesions, positive for CD20 and BCL-2 markers, and negative for CD3, CD5, CD10, CD23, BCL-6 and cyclin D1, in keeping with a MALT lymphoma (Fig. [2](#F2){ref-type="fig"}).

The patient was referred to the hematology clinic of our National Oncology Institute. She remained on 6-month surveillance follow-up with no recurrences in the next 5 years, despite no additional treatments.

Discussion {#sec1_6}
==========

MALT lymphoma is an uncontrolled proliferation of the mucosal B-cell lymphocytes, usually responsible for pathogen elimination. Their prevalence among patients with chronic immune system stimulation supports the belief that continuous replication may lead to DNA errors, some of them with a pro-replication and/or anti-apoptotic effect, leading to cancer cell proliferation \[[@B9]\].

Signs and symptoms are unspecific, with one third of patients clinically asymptomatic at the diagnosis \[[@B10], [@B11]\]. Occasionally patients may present with a cough, dyspnea, chest pain, or even hemoptysis \[[@B7]\]. Fever and weight loss may occur in more aggressive disease forms \[[@B12]\].

The diagnostic approach includes imaging exams, the features of which are unspecific. The most common findings (\>70%) are multiple bilateral lung nodules with air bronchograms. Other radiological presentations described include areas of consolidation and mosaic attenuation pattern. Hilar and mediastinal lymphadenopathy is present in 30% of patients and pleural effusions are seen in 10% of cases \[[@B13], [@B14]\]. The PET-CT can help in the diagnostic approach in some patients, although it is an underutilized imaging exam \[[@B15]\]. The definitive diagnosis is based on the histological exam of samples and depends on experienced pathologists \[[@B16]\].

Due to the low prevalence of disease, there are no prospective randomized controlled trials addressing pulmonary MALT lymphoma treatment. Therefore, the optimal treatment modality remains to be defined \[[@B17]\]. Based on expert opinion and case reports, the successful therapy usually includes radiation therapy or surgical resection for locally controlled disease. For localized disease, some reported cases had spontaneous regression \[[@B18]\]. For widespread tumors, systemic chemotherapy has been used \[[@B19]\].

Conclusion {#sec1_7}
==========

Pulmonary MALT lymphoma is a rare indolent entity with a highly variable clinical presentation. The histological confirmation is frequently difficult to obtain and may involve a surgical biopsy. The thoracic CT features of locally controlled disease are not pathognomonic and can be mistaken for lung adenocarcinoma, a far more common cancer. Due to the few cases reported, there are no international recommendations guiding the therapeutic approach. Therefore, treatment is based on expert opinion, with surgery being the proposed approach for local disease.
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